Stay updated with breaking news from Colin Freund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Modra Pharmaceuticals ("Modra") today announced that the U.S. Patent and Trademark Office (USPTO) has issued to Modra U.S. Patent No. 11,571,408, covering the use of its oral taxane therapeutic ModraDoc006/r.
Explore our extensive collection of articles written by some of the leading experts and scientists from the pharmaceutical industry.
Could oral taxane chemotherapies outperform traditional options? Here, Colin Freund, Modra Pharmaceuticals CEO explores their benefits.
ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficacy levels comparable to intravenous (IV) docetaxel Based on strong
Results support ModraDoc006/r as an effective, convenient, and well tolerated oral docetaxel treatment option for patients with mCRPC Response rates compare favorably to intravenous (IV) docetaxel